Oral ACTH (H.P. Acthar®Gel) inhibits IL-1 and IL-17 secretion in humans - 07/02/12
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/204e.gif)
pages | 4 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objective |
We have shown that oral corticotropin hormone (ACTH) decreased clinical score, inflammatory foci and Teff IL-17 in fed and adoptive transferred recipient mice with experimental autoimmune encephalomyelitis (EAE). Therefore, we determined whether oral administration of ACTH had immunological and endocrinological effects and was safe in humans.
Methods |
Three groups of three healthy adult volunteers were assayed for total serum ACTH, cortisol and a set of pro-inflammatory and counter-regulatory cytokines after ingested dose(s) of ACTH 4 IU (n=3), 41 IU (n=3), or 123 IU (n=3) over 5 days.
Results |
There were no safety issues during the trial. There was no increase in total ACTH levels after day 1 or day 5. There was no significant increase in total cortisol among the groups comparing day 1 to day 5. There were significant decreases in the inflammatory cytokine IL-1 and IL-17 secretion at day 6 compared to baseline with the 123 IU dose but not after the 4 IU and 41 IU doses.
Conclusions |
These data provide evidence for the safety and an immunological effect of oral ACTH in humans. It is unknown if the change in IL-1 and IL-17 reflects a local GI-mediated effect or effects following systemic absorption of ACTH.
Le texte complet de cet article est disponible en PDF.Keywords : ACTH, Corticotropin, Oral proteins, IL-17, IL-1
Plan
Vol 66 - N° 1
P. 36-39 - février 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?